The reported evidence supports a dexamethasone-associated event-free survival advantage accompanied by increased infectious, neuropsychiatric, and musculoskeletal toxicity; it remains an inference requiring prospective testing that hybrid, alternating, or risk-adapted glucocorticoid strategies could preserve benefit while reducing harm.

The supplied record reports that CAR-based therapies and immune checkpoint strategies are being studied in medulloblastoma and that CAR NK therapy may be less prone to some limitations; it is an inference—not demonstrated here—that subgroup-informed antigen selection, checkpoint modulation, and proteomic or liquid-biopsy monitoring could improve efficacy or safety.

The evidence supports an association between pediatric-protocol treatment and improved survival in one non-metastatic adult rhabdomyosarcoma cohort; inferentially, maintaining adequate chemotherapy exposure and including disease-specific agents could improve adult sarcoma outcomes, but this requires confirmation in prospective studies and careful toxicity assessment.

The record supports an association between preserved liver function, absence of extrahepatic metastasis, and better outcomes with first-line atezolizumab/bevacizumab; it remains an inference requiring prospective validation that selecting patients by these features and actively treating underlying liver disease will improve survival.

The reviewed evidence suggests that inhibiting selected non-glycolytic metabolic dependencies may sensitize metabolically defined brain tumors to radiotherapy, immunotherapy, or other treatments; this remains an inferred therapeutic strategy requiring brain-penetrant agents, biomarkers, and prospective clinical validation.

The evidence supports the feasibility and potential prognostic value of targeted-drug and oral-chemotherapy maintenance strategies, including longitudinal ctDNA monitoring; it remains an inference—not proof—that ctDNA-guided maintenance selection could improve outcomes, because the retrospective nonrandomized comparisons did not establish efficacy equivalence or clinical utility.

The trial provides evidence that a 1-cm CTV margin does not significantly increase marginal or out-of-field recurrence; it may therefore reduce irradiation of normal brain while preserving disease control, but reduced toxicity was not reported and the confidence intervals and numerical survival trends do not establish equivalence or noninferiority.

The supplied record reports clinical experience supporting evaluation of adoptive cell therapy safety, feasibility, and efficacy; it further infers that improved cell products and combination therapies could overcome solid-tumor barriers while potentially limiting acute and long-term toxicity, but no specific effective regimen is established in the abstract.

The planned trial will test whether structured aerobic and resistance exercise reduces biomarker- or imaging-defined cardiac dysfunction relative to exercise advice alone; any preventive benefit, quality-of-life improvement, or applicability to pediatric oncology remains hypothetical because no results are reported and eligibility begins at age 18.

The trial provides evidence that this low-dose, slowly escalated oral-immunotherapy protocol can increase peanut tolerance in preschool children; it is an inference—not established by a direct protocol comparison—that slower escalation and lower maintenance dosing are safer than other oral-immunotherapy regimens, and the record provides no pediatric-oncology therapeutic hypothesis.

The evidence supports comparative therapeutic signals for TACE plus resection, TACE plus RFA, and RFA plus 125I in small hepatocellular carcinoma; it may be inferred that these combinations could improve treatment selection, including an RFA-plus-125I option for unresectable disease, but pediatric applicability and benefit for individual patients are not established by the supplied record.

The record supports the practical use of therapy-specific pharmacology frameworks in developing pediatric cell and gene therapies; it is reasonable—but inferential—to hypothesize that better dosing, kinetic monitoring, and preclinical-to-clinical translation could improve treatment selection and safety in pediatric oncology, including CAR-T-cell development.